Tag: Janssen

Janssen will develop a new treatment for chronic hepatitis B

janssen j&j
Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals (USA) for an exclusive, worldwide license to develop and commercialize ARO-HBV.

Janssen and Bayer will close their South Korean facilities

Janssen and Bayer will join global pharmaceutical companies that have pulled their manufacturing facilities out of Korea over rising payroll costs and intensifying conflicts with unions.

EUSA Pharma buys global rights to Sylvant drug from Janssen

EUSA Pharma announced that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland to acquire the global rights to SYLVANT® (siltuximab).

Janssen stops the trials of Daratumumab

janssen j&j
Genmab announced that the DMC has recommended that the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy should be terminated.

Janssen Biotech will buy BeneVir Biopharm

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.

BMS will collaborate with Janssen on a novel cardiovascular therapy

Bristol-Myers Squibb announced a worldwide collaboration with Janssen Pharmaceuticals on a Factor XIa inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa inhibitor.

Janssen intends to manufacture bedaquiline at the Pharmstandard plant in Ufa

Janssen Pharmaceutica N.V., a part of Janssen Pharmaceutical Companies of Johnson & Johnson, signed a memorandum of intent with Pharmstandard JSC to manufacture and supply Sirturo®, a medicinal product.

Theravance Biopharma and Janssen entered into drug development collaboration

Theravance Biopharma Ireland announced that it has entered into a global co-development and commercialization agreement with Janssen Biotech, Inc., for TD-1473 and related back-up compounds for inflammatory intestinal diseases

Johnson & Johnson Innovation creates a research incubator in Belgium

test tubes
The Belgium-based JLINX incubator – a collaboration launched in March 2016 between Janssen Pharmaceutica NV and Bioqube Ventures – will become part of the global Johnson & Johnson Innovation network

Janssen entered into collaboration with Chinese Genscript Biotech

janssen j&j
Janssen Biotech has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited

SKOLKOVO Foundation and Janssen signed a collaboration agreement

Kirill Kaem, Senior Vice-President at SKOLKOVO Foundation, and Luis Diaz-Rubio, Managing Director at Janssen, signed a collaboration agreement

Janssen and Zymeworks become partners in drug development

drug development
Zymeworks Inc announced it has executed a licensing agreement with Janssen Biotech

First anti-CD38 monoclonal antibody is registered in the Russian Federation

janssen j&j
Janssen announced the market launch of Darzalex, a drug that received the certificate of state registration in the Russian Federation

BioMed X and Janssen will cooperate on biomedical research projects

The BioMed X Innovation Center announced today a collaboration agreement with Janssen Research & Development to foster early-stage preclinical biomedical research and development projects

Janssen Sciences starts an expansion of its facility in Ireland

janssen j&j
Janssen Sciences, a a subsidiary of Johnson & Johnson, announced an expansion of its Irish facility located in Cork

Janssen entered into license agreement with Provention Bio

janssen j&j
Provention Bio announced today that it has entered into agreements with Janssen to in-license two clinical-stage assets